SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Klinisk medicin) hsv:(Neurologi) "

Sökning: hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Klinisk medicin) hsv:(Neurologi)

  • Resultat 21-30 av 10215
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
21.
  • Nilsson, Christer, et al. (författare)
  • Tracking the neurodegeneration of parkinsonian disorders - A pilot study
  • 2007
  • Ingår i: Neuroradiology. - : Springer Science and Business Media LLC. - 1432-1920 .- 0028-3940. ; 49:2, s. 111-119
  • Tidskriftsartikel (refereegranskat)abstract
    • The purpose of the study was to explore the possibilities of using diffusion tensor imaging (DTI) and tractography (DTT) for the differential diagnosis and monitoring of disease progression in idiopathic Parkinson's disease (IPD), compared with the atypical parkinsonian disorders multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). A 3.0-T MR scanner was used. DTI was acquired using a single-shot EPI sequence with diffusion encoding in 32 directions and a voxel size of 2×2×2 mm3. DTI data were analysed and DTT was performed using the PRIDE fibre tracking tool supplied by the manufacturer. The fractional anisotropy (FA) and apparent diffusion coefficient (ADC) within each tract were determined. DTI and DTT images in patients with moderate to advanced MSA demonstrated degeneration of the middle cerebellar peduncles and pontine crossing tracts, with decreased FA and increased ADC. This accounted for most of the pontine and cerebellar atrophy characteristic of this disease. In contrast, patients with PSP showed a selective degeneration of the superior cerebellar peduncle. Three-dimensional images of whole-brain white matter tracts demonstrated a reduction of cortical projection fibres in all patients with PSP. Visualization of the selective degeneration of individual fibre tracts, using DTI and DTT, adds qualitative data facilitating the differential diagnosis of parkinsonian disorders. Repeated measurements of FA and ADC values in a whole fibre tract might be used for monitoring disease progression and studying the effect of treatment in neuroprotective trials. The results are preliminary considering the small number of subjects in the study. © Springer-Verlag 2007.
  •  
22.
  • Westman, Klara, et al. (författare)
  • Effect of liraglutide on markers of insulin production in persons with type 2 diabetes treated with multiple daily insulin injections
  • 2022
  • Ingår i: Journal of Diabetes and its Complications. - : Elsevier BV. - 1056-8727 .- 1873-460X. ; 36:3
  • Tidskriftsartikel (refereegranskat)abstract
    • In this post-hoc analysis of data from a randomised clinical trial, we compared the effect of liraglutide to placebo on markers of insulin secretion in persons with type 2 diabetes treated with multiple daily insulin injections. Liraglutide increased insulin secretion, measured by C-peptide, by 19% after 24 weeks of treatment. Clinical trial registration: EudraCT 2012-001941-42.
  •  
23.
  • Burman, Joachim, et al. (författare)
  • Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis : the Swedish experience
  • 2014
  • Ingår i: Journal of Neurology, Neurosurgery and Psychiatry. - London, United Kingdom : BMJ Publishing Group Ltd. - 0022-3050 .- 1468-330X. ; 85:10, s. 1116-1121
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Autologous haematopoietic stem cell transplantation (HSCT) is a viable option for treatment of aggressive multiple sclerosis (MS). No randomised controlled trial has been performed, and thus, experiences from systematic and sustained follow-up of treated patients constitute important information about safety and efficacy. In this observational study, we describe the characteristics and outcome of the Swedish patients treated with HSCT for MS.Methods: Neurologists from the major hospitals in Sweden filled out a follow-up form with prospectively collected data. Fifty-two patients were identified in total; 48 were included in the study and evaluated for safety and side effects; 41 patients had at least 1 year of follow-up and were further analysed for clinical and radiological outcome. In this cohort, 34 patients (83%) had relapsing-remitting MS, and mean follow-up time was 47 months.Results: At 5 years, relapse-free survival was 87%; MRI event-free survival 85%; expanded disability status scale (EDSS) score progression-free survival 77%; and disease-free survival (no relapses, no new MRI lesions and no EDSS progression) 68%. Presence of gadolinium-enhancing lesions prior to HSCT was associated with a favourable outcome (disease-free survival 79% vs 46%, p=0.028). There was no mortality. The most common long-term side effects were herpes zoster reactivation (15%) and thyroid disease (8.4%).Conclusions: HSCT is a very effective treatment of inflammatory active MS and can be performed with a high degree of safety at experienced centres.
  •  
24.
  • Gulati, Sasha, et al. (författare)
  • Risk of intracranial hemorrhage in users of oral antithrombotic drugs: Study protocol for a nationwide study
  • 2015
  • Ingår i: F1000 Research. - : F1000 Research Ltd. - 2046-1402. ; 4
  • Tidskriftsartikel (refereegranskat)abstract
    • Background A wide range of antithrombotic medications can be used in the prevention and treatment of thrombosis. Among hemorrhagic complications of antithrombotic drugs, intracranial hemorrhage may have particularly devastating consequences with high morbidity, disability and mortality rates. The incidence and risks of intracranial hemorrhage in patients on antithrombotic treatments from regular clinical practice outside clinical trials remain largely unknown. It is not known if results from clinical trials can be extrapolated to everyday clinical practice. We will conduct a nationwide study to investigate the risks and incidence rates of intracranial hemorrhage in users oral antithrombotic drugs in Norway from 2008 through 2014. Methods and design The aim of this nationwide study is to investigate the incidence rates of intracranial hemorrhage requiring hospitalization in users of oral antithrombotic drugs. The study will be conducted within the approximately 4.7 million inhabitants of Norway from January 1st, 2008, to December 31st, 2014. Treatment and outcome data are obtained from the Norwegian patient registry and the Norwegian prescription database.
  •  
25.
  •  
26.
  •  
27.
  •  
28.
  • Nord, Maria (författare)
  • Levodopa pharmacokinetics -from stomach to brain : A study on patients with Parkinson’s disease
  • 2017
  • Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
    • Parkinson’s disease (PD) is one of the most common neurodegenerative disorders and it is caused by a loss of dopamine (DA) producing neurons in the basal ganglia in the brain. The PD patient suffers from motor symptoms such as tremor, bradykinesia and rigidity and treatment with levodopa (LD), the precursor of DA, has positive effects on these symptoms. Several factors affect the availability of orally given LD. Gastric emptying (GE) is one factor and it has been shown to be delayed in PD patients resulting in impaired levodopa uptake. Different enzymes metabolize LD on its way from the gut to the brain resulting in less LD available in the brain and more side effects from the metabolites. By adding dopa decarboxylase inhibitors (carbidopa or benserazide) or COMT-inhibitors (e.g. entacapone) the bioavailability of LD increases significantly and more LD can pass the blood-brain-barrier and be converted to DA in the brain. It has been considered of importance to avoid high levodopa peaks in the brain because this seems to induce changes in postsynaptic dopaminergic neurons causing disabling motor complications in PD patients. More continuously given LD, e.g. duodenal or intravenous (IV) infusions, has been shown to improve these motor complications. Deep brain stimulation of the subthalamic nucleus (STN DBS) has also been proven to improve motor complications and to make it possible to reduce the LD dosage in PD patients.In this doctoral thesis the main purpose is to study the pharmacokinetics of LD in patients with PD and motor complications; in blood and subcutaneous tissue and study the effect of GE and PD stage on LD uptake and the effect of continuously given LD (CDS) on LD uptake and GE; in blood and cerebrospinal fluid (CSF) when adding the peripheral enzyme inhibitors entacapone and carbidopa to LD infusion IV; in brain during STN DBSand during oral or IV LD treatment.To conclude, LD uptake is more favorable in PD patients with less severe disease and GE is delayed in PD patients. No obvious relation between LD uptake and GE or between GE and PD stage is seen and CDS decreases the LD levels. Entacapone increases the maximal concentration of LD in blood and CSF. This is more evident with additional carbidopa and important to consider in avoiding high LD peaks in brain during PD treatment. LD in brain increases during both oral and IV LD treatment and the DA levels follows LD well indicating that PD patients still have capacity to metabolize LD to DA despite probable pronounced nigral degeneration. STN DBS seems to increase putaminal DA levels and together with IV LD treatment also increases LD in brain possibly explaining why it is possible to decrease LD medication after STN DBS surgery.
  •  
29.
  • Ramgren, B, et al. (författare)
  • Vertebrobasilar dissection with subarachnoid hemorrhage: a retrospective study of 29 patients.
  • 2005
  • Ingår i: Neuroradiology. - : Springer Science and Business Media LLC. - 1432-1920 .- 0028-3940. ; 47:2, s. 97-104
  • Tidskriftsartikel (refereegranskat)abstract
    • We have reviewed initial diagnostic features, treatment, and outcome in 29 patients with acute subarachnoid hemorrhage due to non-traumatic vertebrobasilar artery dissection diagnosed in our hospital between 1993 and 2003. The dissections occurred in the vertebral artery in 19 patients, the posterior inferior cerebellar artery ( PICA) in two patients, the basilar artery in four patients, and in the vertebral artery extending into the PICA in four patients. A pseudoaneurysm was found in 20 patients. Clinical manifestations typically included sudden onset of moderate to severe headache, nuchal rigidity, and drowsiness. Fourteen patients were treated conservatively. Fifteen patients underwent endovascular treatment with either parent artery occlusion ( 13 patients) or aneurysmal coil occlusion with preservation of the parent artery ( 2 patients). Re-bleeding occurred within 12 days and before treatment in nine patients. Eight of these had a pseudoaneurysm. No patient bled after endovascular treatment. Poor grade and early re-bleeding were associated with less favorable outcome. Outcome at 6 months did not differ significantly between endovascular and conservative treatment. Altogether, good recovery was achieved for 16 patients, moderate disability was seen in one, severe disability in four, and eight patients ( 27%) died. The absence of bleeding subsequent to endovascular treatment in this study suggests that endovascular treatment may be a rational approach in these patients at high risk of re-bleeding, especially those with a pseudoaneurysm.
  •  
30.
  • Religa, D., et al. (författare)
  • SveDem, the Swedish Dementia Registry - A tool for improving the quality of diagnostics, treatment and care of dementia patients in clinical practice
  • 2015
  • Ingår i: PLoS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 10:2
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: The Swedish Dementia Registry (SveDem) was developed with the aim to improve the quality of diagnostic work-up, treatment and care of patients with dementia disorders in Sweden. Methods: SveDem is an internet based quality registry where several indicators can be followed over time. It includes information about the diagnostic work-up, medical treatment and community support (www.svedem.se). The patients are diagnosed and followed-up yearly in specialist units, primary care centres or in nursing homes. Results: The database was initiated in May 2007 and covers almost all of Sweden. There were 28 722 patients registered with a mean age of 79.3 years during 2007-2012. Each participating unit obtains continuous online statistics from its own registrations and they can be compared with regional and national data. A report from SveDem is published yearly to inform medical and care professionals as well as political and administrative decision-makers about the current quality of diagnostics, treatment and care of patients with dementia disorders in Sweden. Conclusion: SveDem provides knowledge about current dementia care in Sweden and serves as a framework for ensuring the quality of diagnostics, treatment and care across the country. It also reflects changes in quality dementia care over time. Data from SveDem can be used to further develop the national guidelines for dementia and to generate new research hypotheses.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 21-30 av 10215
Typ av publikation
tidskriftsartikel (8464)
forskningsöversikt (580)
konferensbidrag (552)
doktorsavhandling (313)
bokkapitel (214)
annan publikation (58)
visa fler...
bok (12)
samlingsverk (redaktörskap) (7)
licentiatavhandling (7)
rapport (5)
konstnärligt arbete (2)
recension (2)
visa färre...
Typ av innehåll
refereegranskat (8876)
övrigt vetenskapligt/konstnärligt (1303)
populärvet., debatt m.m. (35)
Författare/redaktör
Hansson, Oskar (392)
Zetterberg, Henrik, ... (381)
Blennow, Kaj, 1958 (357)
Stibrant Sunnerhagen ... (303)
Norrving, Bo (260)
Minthon, Lennart (230)
visa fler...
Büki, Andras, 1966- (133)
Palmqvist, Sebastian (122)
Stomrud, Erik (120)
Lindgren, Arne (118)
Odin, Per (113)
Nyholm, Dag (112)
Londos, Elisabet (109)
Landtblom, Anne-Mari ... (106)
Ossenkoppele, Rik (106)
Tatlisumak, Turgut (103)
Hariz, Marwan (100)
Janelidze, Shorena (98)
Hagell, Peter (97)
Blennow, Kaj (96)
Piehl, F (95)
Olsson, T (93)
Hillert, J (92)
Blomstedt, Patric (92)
Lindvall, Olle (92)
Blomstrand, Christia ... (91)
Marklund, Niklas (90)
Zetterberg, Henrik (90)
Enblad, Per (86)
Englund, Elisabet (83)
Burman, Joachim, 197 ... (83)
Jood, Katarina, 1966 (82)
Wallin, Anders, 1950 (79)
Scheltens, Philip (79)
Mattsson-Carlgren, N ... (78)
Sharma, Hari Shanker (78)
Frisén, Lars, 1939 (77)
Forsgren, Lars (76)
Svenningsson, Anders (76)
Koskinen, Lars-Owe D ... (75)
van Westen, Danielle (74)
Sharma, Aruna (73)
Jakola, Asgeir Store (73)
Gunnarsson, Martin, ... (72)
Widner, Håkan (72)
Olsson, Tomas (70)
Rosén, Ingmar (69)
Nilsson, P. (68)
Edvinsson, Lars (68)
Puschmann, Andreas (68)
visa färre...
Lärosäte
Lunds universitet (3448)
Göteborgs universitet (2551)
Karolinska Institutet (2318)
Uppsala universitet (2199)
Umeå universitet (1563)
Örebro universitet (861)
visa fler...
Linköpings universitet (670)
Stockholms universitet (394)
Jönköping University (194)
Kungliga Tekniska Högskolan (182)
Chalmers tekniska högskola (170)
Högskolan i Skövde (91)
Högskolan Kristianstad (81)
Luleå tekniska universitet (80)
Högskolan Dalarna (75)
Linnéuniversitetet (70)
Mälardalens universitet (36)
Mittuniversitetet (35)
Malmö universitet (33)
Karlstads universitet (28)
Sveriges Lantbruksuniversitet (26)
Gymnastik- och idrottshögskolan (25)
Marie Cederschiöld högskola (24)
VTI - Statens väg- och transportforskningsinstitut (21)
RISE (20)
Högskolan i Borås (15)
Högskolan Väst (14)
Röda Korsets Högskola (14)
Högskolan i Halmstad (13)
Högskolan i Gävle (13)
Södertörns högskola (9)
Blekinge Tekniska Högskola (9)
Sophiahemmet Högskola (6)
Handelshögskolan i Stockholm (4)
Konstfack (1)
Försvarshögskolan (1)
visa färre...
Språk
Engelska (9884)
Svenska (285)
Ungerska (23)
Tyska (9)
Odefinierat språk (4)
Norska (2)
visa fler...
Spanska (2)
Franska (1)
Danska (1)
Ryska (1)
Italienska (1)
Finska (1)
Kinesiska (1)
visa färre...
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (10214)
Samhällsvetenskap (411)
Naturvetenskap (214)
Teknik (163)
Humaniora (75)
Lantbruksvetenskap (9)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy